SunTrust Downgrades Intra-Cellular Therapies (ITCI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
JMP Securities Downgrades Intra-Cellular Therapies (ITCI) to Market Perform
September 29, 2016 6:52 AM EDTJMP Securities downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Market Outperform to Market Perform and removed its price target (prior $55.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $42.35 yesterday.
... MoreIntra-Cellular Therapies (ITCI) Announces ITI-007 Phase 3 Missed Primary Endpoint in Schizophrenia
September 28, 2016 4:03 PM EDTIntra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo. This replicates the... More
